MORE VIDEOS
Explore more

Lung Cancer - Small Cell

Small Cell Lung Cancer Explained
Small Cell Lung Cancer Explained administrator 1 Views • 2 years ago

Small cell lung cancer (SCLC) is a less common type of lung cancer, found in approximately 13% of all lung cancer patients. This video defines this type of lung cancer, its stages, and how GO2 Foundation for Lung Cancer can help.
Histopathology Lung--Small cell carcinoma
Histopathology Lung--Small cell carcinoma administrator 2 Views • 2 years ago

Histopathology Lung--Small cell carcinoma
Frontline Therapy Approaches for Small Cell Lung Cancer
Frontline Therapy Approaches for Small Cell Lung Cancer administrator 2 Views • 2 years ago

Treatment responses commonly seen in patients who are treated with chemotherapy as a frontline option for extensive-stage small cell lung cancer, and considerations for using a regimen that includes atezolizumab up front.
Advice for Patients With Small Cell Lung Cancer
Advice for Patients With Small Cell Lung Cancer administrator 3 Views • 2 years ago

Cancer specialists provide closing thoughts and recommendations for advocacy and support groups for patients with advanced small cell lung cancer.

View more at http://curetoday.com/

CURE: Combining science and humanity to make cancer understandable.

What kind of surgery is used for non-small cell lung cancer (NSCLC)?
What kind of surgery is used for non-small cell lung cancer (NSCLC)? administrator 5 Views • 2 years ago

Learn more about lung cancer at http://www.YouAndLungCancer.com
Surgery for non-small cell lung cancer is quite varied. There is no “one size fits all” because it depends on multiple factors. First of all, it depends on the location of the cancer. Secondly, it depends on the extent of the cancer, for example, to what extent does it involve the lymph nodes and the middle of the chest. Thirdly, it depends on the “cardiopulmonary reserve” of the patient. That includes factors like the amount of normal lung that can be spared from the surgery to ensure that the patient has sufficient lung function after the surgery is completed. The different types of surgery explained in this video are wedge resection, lobectomy, and pneumonectomy.

Osimertinib in Advanced Non–Small-Cell Lung Cancer
Osimertinib in Advanced Non–Small-Cell Lung Cancer administrator 2 Views • 2 years ago

EGFR tyrosine kinase inhibitors are standard treatment for non small-cell lung cancer. Despite high tumor response rates, disease progresses in most patients after 9 to 13 months. Is there a way to lengthen progression-free survival? New research findings are summarized in this short video. Full study: http://nej.md/2gymJkj

Unlocking the Secrets of Small Cell Lung Cancer: What You Need to Know Now!
Unlocking the Secrets of Small Cell Lung Cancer: What You Need to Know Now! administrator 0 Views • 2 years ago

The World Conference of Lung Cancer has brought about a game-changing breakthrough for lung cancer patients. Lung cancer is the leading cause of cancer death among all Americans, surpassing breast cancer, colon cancer, and prostate cancer combined. However, new trends in small cell lung cancer research have brought about hope for those who are affected by this deadly disease.


One of the latest trends in small cell lung cancer research is the development of targeted therapies. These therapies are designed to specifically target cancer cells, while sparing healthy cells. This can result in fewer side effects and a better quality of life for patients. Furthermore, clinical trials have shown promising results in the use of immunotherapy, which harnesses the body's own immune system to fight cancer.


Another trend in small cell lung cancer research is the use of liquid biopsies. This non-invasive test can detect cancer cells in a patient's blood, allowing for earlier detection of small cell lung cancer. Early detection is crucial in the treatment of lung cancer, as it can result in a better prognosis and an increased chance of survival.


Finally, advancements in genetic testing have allowed doctors to tailor treatments to individual patients. By analyzing a patient's genetic makeup, doctors can determine which treatments will be most effective for that patient. This personalized approach to treatment has resulted in better outcomes and a higher quality of life for small cell lung cancer patients.


In conclusion, the new trends in small cell lung cancer research are bringing about hope for those who are affected by this deadly disease. Targeted therapies, immunotherapy, liquid biopsies, and personalized treatments are all promising avenues for the future of small cell lung cancer treatment. With continued research and advancements in technology, we can hope for a future where small cell lung cancer is no longer a death sentence.
Small cell lung cancer may respond to combination of immunotherapy and targeted therapy
Small cell lung cancer may respond to combination of immunotherapy and targeted therapy administrator 1 Views • 2 years ago

Researchers at MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair, such as PARP inhibitors, achieved dramatic tumor reduction in mouse models of small cell lung cancer. The findings, published in Cancer Discovery, suggest a promising new approach for treating patients with this aggressive form of lung cancer.

Lauren Averett Byers, M.D., corresponding author on the study and assistant professor in Thoracic/Head and Neck Medical Oncology at MD Anderson, discusses the study's findings.

For more information, visit https://www.mdanderson.org/new....sroom/small-cell-lun

Request an appointment at MD Anderson by calling 1-877-632-6789 or by completing an online self-referral form: https://my.mdanderson.org/Requ....estAppointment?cmpid

Immunotherapy Advances in Small Cell Lung Cancer
Immunotherapy Advances in Small Cell Lung Cancer administrator 4 Views • 2 years ago

Small cell lung cancer (SCLC) is aggressive and often difficult to treat, but many patients may have new hope. https://www.cancerresearch.org/webinars

On August 17, 2018, the FDA approved the first immunotherapy—the checkpoint inhibitor nivolumab (Opdivo®, Bristol-Myers Squibb)—for patients with small cell lung cancer. Since this approval, there has been renewed focus on how to make different immunotherapies work for a disease which typically comprises 10-15% of all lung cancer cases.

In this webinar for patients and caregivers, Matthew Hellmann, M.D., of Memorial Sloan Kettering Cancer Center discusses the new FDA approval, clinical trials, and potential treatments for patients with small cell lung cancer.

Matthew Hellman MSKDr. Matthew Hellmann specializes in the care of patients with lung cancers. He is dedicated to identifying better treatments for people with all stages of disease and to providing compassionate care for patients and their families. His research focuses on developing innovative and effective ways to harness the body’s immune system to fight cancer. He is a member of the Immunotherapeutics Group, which designs and leads early-phase clinical trials of immunotherapies for patients with a variety of different cancers.

The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is hosted by our science writer, Arthur Brodsky, Ph.D. This special episode in our webinar series is made possible with generous support from Bristol-Myers Squibb.

Browse our Cancer Immunotherapy and You Webinar Series playlist on YouTube or visit the Webinars page on our website to see other webinars in this series.

https://www.cancerresearch.org/webinars

The Basics of Immunotherapy in Small Cell Lung Cancer (SCLC)
The Basics of Immunotherapy in Small Cell Lung Cancer (SCLC) administrator 2 Views • 2 years ago

Earn CME for related activities: https://hmpeducation.com/

Showing 21 out of 22